252 Teva Pharmaceuticals Photos and Premium High Res Pictures - Getty Images
Teva Cites 'Havoc' as It Takes Drug Label Spat to Supreme Court (1)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/CCBS56SBRRKUDM7JEVVE3UOQEE.jpg "Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters")
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters
Teva Hit With New Lawsuit Over Proposed Korlym Drug Copy
Teva Considering Cutting up to 10,000 Jobs: Bloomberg
Teva Offers Drugs Valued at $23 Billion to End Opioid Suits - Bloomberg
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
Teva's Trouble Was Predicted. Path to Recovery Not as Clear - Bloomberg
Teva Is 'on the Way' to Leaving Opioid Litigation Behind, CEO Says | Barron's
Teva's Adderall Shortage Seen Continuing Into March (TEVA) - Bloomberg
Future Teva CEO Seeks to 'Formulate Clear Strategy' - YouTube
Teva Pharmaceuticals Could Face Billions in Damages From Opioid Lawsuits | Barron's
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva to lay off 25% of workforce, suspends dividend - BNN Bloomberg
With New Teva Deal, Combined NY Settlements With Opioid Makers Top $2 Billion | New York Law Journal
Teva: Now What? | Barron's
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Justice Dept reportedly may file charges in its generic-drug probe by year-end
Teva says its generic Adderall shortage will last another 2 to 3 months (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva Pharmaceutical to Replace CEO Kare Schultz - WSJ
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
Teva CEO Kare Schultz Says Drugmaker Will Fight US Price-Fixing Charges - Bloomberg
